Verana Health has announced enhancements to its data and software solutions aimed at improving clinical insights and accelerating research timelines. The company—the exclusive analytics partner for the AAO’s IRIS (Intelligent Research in Sight) Registry—reported integration between its Site Explorer tool and Verana Trial Connect (VTC), enabling sponsors and contract research organizations to identify eligible trial patients more efficiently and to track enrollment conversion.

Additionally, Verana Health introduced 2 new variables to its Ophthalmology Qdata modules: corneal staining for dry eye disease and diplopia for thyroid eye disease, expanding the capacity for real-world analysis of disease progression and treatment outcomes. The company also reports it has expanded its MIPS Advisory Services to provide coaching and compliance guidance for ophthalmology practices.

At the AAO’s 2025 annual meeting October 18-20 in Orlando, Florida, Verana Health will present sessions highlighting its expanded MIPS Advisory Services, joint research with Stanford University on using natural language processing to study thyroid eye disease in the IRIS Registry, and a presentation on how registry participation can streamline MIPS reporting.